tirzepatide weight loss vs semaglutide Semaglutide: A Comprehensive Comparison for Tirzepatide vs Semaglutide for Weight

At Rixa Health , we take a personalized approach to GLP-1 treatment that addresses these exact challenges

Its physiological actions include: Increasing glucose-dependent insulin secretion Suppressing glucagon release Delaying gastric emptying Reducing appetite and caloric intake Enhancing satiety Improving insulin sensitivity Promoting weight reduction The major limitation of native GLP-1 is its ultra-short half-life due to rapid degradation by DPP-4 enzymes

Key Considerations for Obese Patients: Bowel Preparation : Obesity is a significant factor in poor bowel preparation, often necessitating more intensive or extended prep protocols to ensure adequate cleansing

"We are thrilled that today's findings showed the superior weight loss of [tirzepatide], which helped patients achieve 47% more relative weight loss compared to [semaglutide]

In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms

Aim for 1.2 to 1.6 grams of protein per kilogram of body weight daily, prioritizing protein at every meal